The c-MET-mutation-targeted NSCLC drugs that are being developed by Korean pharma and biotech companies have been recognized for their potential. Recently, Abion Bio signed an agreement with Janssen to receive Leclaza (lasertinib) free of charge. This agreement will allow Abion Bio to commercialize the combination of its in-development vabametkib and Leclaza for the treatment of lung cancer. InnoCure Therapeutics’s targeted therapy has been recognized for its value by being selected as a national new drug development project

According to industry sources on the 13th, Johnson & Johnson’s subsidiary Janssen will provide domestic biotech Abion Bio free lasertinib for its EGFR-positive non-small cell